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ABSTRACT 
Objective: The eukaryotic translational initiation factor 3A (eIF3A) is reported to be over expressed in most breast cancer cells. In the present study, 
our aim is to suppress the over expression of eIF3A in human breast cancer MCF-7 cell line using gene silencing technique (RNA interference (RNAi)). 
Methods: The artificial microRNA (amiRNA) targeting eIF3A gene was constructed by incorporating short interference RNA (siRNA) sequences 
against eIF3A gene into endogenous microRNA30 (miR-30) and cloned into pcDNA3.1 vector. The amiRNA containing plasmid was then transfected 
into MCF-7 cell line and the expression of eIF3A was examined by RT-PCR. The cytotoxicity of plasmid with amiRNA targeting eIF3A on MCF–7 cells 
was evaluated by MTT assay. 
Results: The amiRNA construct significantly inhibited eIF3A gene expression and reduce the cell viability of MCF-7 cell line. 
Conclusion: The usage of modified endogenous amiRNA in vector based expression system with significant gene silencing efficiency suggests that 
RNAi based gene silencing method can be considered as one of the effective means to control cancer. 
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INTRODUCTION 
Breast cancer is the most common cancer affecting women 
worldwide, comprising 16% of all female cancers. In 2011, an 
estimated 230 480 new cases of invasive breast cancers were 
diagnosed among women, in addition to an estimated 57 650 cases 
of in situ breast cancer and approximately 39 520 women are 
expected to die from breast cancer [1]. Standard cancer therapy 
generally combines surgery, multi-therapeutic agents and ionizing 
radiation [2]. Major issues concerning conventional anticancer 
chemotherapy are the side effects induced by the non-specific 
targeting of both normal and cancer cells and the emergence of 
drug-resistance in cancer cells [3]. Prevention and treatment of 
breast cancer require a better understanding of the molecular 
mechanisms underlying the progression of breast cancer. Currently, 
there has been growing interest in the use of RNAi technology to 
regulate gene expression at different levels.  
One important regulation of gene expression in eukaryotes occurs at 
the level of mRNA translation, specifically at the levels of initiation of 
translation. Eukaryotic initiation factors (eIFs) have been reported 
to play an important role in translation initiation, which controls cell 
growth and proliferation [4]. It has been well documented that 
altering the expression level or the function of eIFs influences the 
synthesis of some proteins and consequently causes abnormal cell 
growth and malignant transformation [5]. P170, the largest putative 
subunit of eIF3, has been found in elevated levels in human breast, 
cervical, esophageal, and lung cancers, suggesting that p170 may 
have a potential role in malignant transformation and/or cell growth 
control [6]. The expression of eIF3 subunits has been found altered 
in various human tumors and their altered expression may cause 
cancer and affect prognosis [7]. It has been well documented that 
eIF3 has been over expressed in numerous cancers [8-10]. Normally 
it binds to S6K1 and remains inactive. Upon stimulation either by 
mitogens, growth factors or drugs, mTOR/Raptor complex gets 
activated and in turn binds and phosphorylates S6K1, leading to its 
dissociation from eIF3. The phosphorylated S6K1 is further 
phosphorylated by PDK1 which activates the S6K1 kinase which in 
turn phosphorylates eIF4B, S6 and other protein targets [11]. The 
20S Proteosome specifically cleaves eIF3a, the largest subunit of 
eIF3, and differentially affects translation of different mRNAs and 
these findings clearly establish that eIF3 is a pivotal player in 
translational control [12]. 
The RNAi technology is an effective gene silencing method [13]. The 
RNAi pathway is activated by a double-stranded RNA (dsRNA) 
“trigger,” which is then processed into short, 21-to 22-nucleotide 
dsRNAs, referred to a siRNAs by the cellular enzyme Dicer. The 
siRNAs become incorporated into the RNA induced silencing 
complex (RISC), in which the siRNA serves as a guide to identify the 
homologous mRNA for destruction. In mammalian cells, dsRNA 
longer than 30 nucleotides triggers the interferon pathway, 
activating RNA-dependent protein kinase (PKR) and 2'-5'-
oligoadenylate synthetase rather than RNAi.  
However, shorter siRNAs exogenously introduced into mammalian 
cells or transcribed endogenously bypass the Dicer step and directly 
activate homologous mRNA degradation without initiating the 
interferon response [14]. There is a possibility of knockdown of 
unknown target gene without RNAi processing mechanism by using 
siRNA in microRNA (miRNA). The use of miRNA has added advantage 
that it eliminates an immune response. miR-30 is a small non-coding 
RNA that regulates gene expression of eukaryotic cells. miRNAs is 
transcribed as ~70 nucleotide stem-loop precursor and subsequently 
processed by the Dicer enzyme to give a mature ~22 nucleotide 
products. The mature miRNA sequences are thought to have 
regulatory roles through complementarities to target mRNA [15]. 
In this study, artificial miRNA (amiRNA) expressing-vector targeting 
eIF3A gene was synthesized and transfected into human breast 
cancer cell line MCF-7. The levels of eIF3A mRNA expression and the 
cytotoxic profile in MCF-7 cells were investigated. 
MATERIALS AND METHODS 
Designing and synthesis of amiRNA 
The target eIF3A mRNA sequence was retrieved from NCBI 
(Reference Sequence: NM_003750.2) and the target siRNA 
sequences were designed by using online siRNA Target Finder, 
(Ambion Inc; Dharmacon; Genescript). After verifying for homology 
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using BLAST, they were incorporated in the stem regions of miR-30 
hairpins. The resulting artificial miRNAs was aligned and analyzed 
for the secondary structure using the web based RNA structure 
prediction tool. Based on the secondary structures the target 
sequence was selected coding regions 1408–1426 (5’–
CCGGAATTGCAGCAGTATG–3’). 
To develop amiRNA construct, 91-nucleotide long modified miR-30 
hairpins for the target mRNAs, flanked by artificial sequences were 
chemically synthesized (Sigma-Aldrich, USA). Sense and antisense 
strands of the target siRNAs were included in the stem region of the 
artificial miR-30 hairpins. Since the natural miR-30 shape is 
essential for Drosha recognition and processing, loop sequences of 
the natural miR-30 and the distal A/C mismatch are included in the 
artificial miR-30 hairpins. 
Two universal primers (32 nt) were designed and synthesized 
(Sigma-Aldrich, USA). The 5’ primer includes sequence of 5’ flanking 
region of miR-30, BamH1 and SpeI restriction sites and a 13 nt 
complementary overlap to the artificial miR-30 at its 3’ end. The 3’ 
primer contains reverse complement sequence of 3’ flanking region 
of miR-30, XbaI restriction site and a 21 complementary overlap to 
the artificial miR-30 at its 3’ end (table 1). The artificial miRNAs 
were synthesized by PCR using the following PCR program: initial 
denaturation temperature 94 for 5 min, loop of 30 cycles of 15 sec 
with annealing at 54 ˚C, 30 sec and a final extension for 10 min at 72 
˚C. The PCR products were resolved on a 1% agarose gel, extracted 
and purified using gel elution kit (Invitrogen, USA). 
Prediction of amiRNA secondary structure 
The secondary structure of amiRNA sequences was analyzed for its 
stability using the web based tool (http://www. ncrna. org/ 
centroidfold/). 
Construction of amiRNA expressing vector targeting eIF3A gene 
The purified PCR products were double restricted with BamH1/XbaI and 
cloned into similarly treated pcDNA 3.1 plasmid vector which contains 
GFP expression sequences, transfected into (E. coli) DH5-α cells and 
stored. After selective culture, recombined plasmid was extracted from 
DH5-α using Medipreps DNA purification system (Qiagen).  
Conformation of transformed clones by colony PCR 
Colony PCR was performed to confirm the presence of transformed 
clones in the selected colonies (GeNet Bio, Bangalore). The PCR 
program was performed using 5 µg of DNA template and forward 
primer 5’ GGATCCACTAGTTATTGCTCTCGAGAGTGAGC 3’ and 
reverse primer 5’TCTAGACCCTTGAATTCCTCGGCAGTGGGCAG3’ 
(Sigma-Aldrich, USA) with initial denaturation at 94 ˚C for 5 min, 
loop of 30 cycles of 30 sec with annealing at 54 ˚C for 30 sec and a 
final extension at 72 ˚C for 10 min. The program was set in a thermo 
cycler and the template was amplified. The amplified products were 
loaded in 1 % agarose gel and positive clones were selected. 
Cell culture and transfection of recombinant plasmid 
The human breast adenocarcinoma cell line (MCF-7) obtained from 
NCCS was maintained in DMEM Medium (GIBCO, Invitrogen) 
supplemented with 10% heat inactivated FBS, 2 mM L-glutamine 
(GIBCO, Invitrogen) and 100 U/ml penicillin-streptomycin (GIBCO). 
The vectors containing cloned DNA sequence for amiRNA was 
maintained in (E. coli) DH5-α cells. The plasmid DNA was isolated, 
gel purified, mixed with lipofectamine 2000 reagent (Invitrogen, 
USA) according to the manufacturer's instructions and used for the 
transfection experiments. 
Reverse transcriptase polymerase chain reaction (RT-PCR) 
To check the silencing efficiency, MCF-7 (1×104
The resultant cDNAs were used in PCR reactions with gene specific 
primers and the products were gel electrophoresed. The PCR 
primers used to amplify eIF3A: forward 5'GTTGGATGATGATC 
GAGGAC3', and reverse 5'GTCCCTGTCGTCTC TTAGAT3’, GAPDH: 
forward 5-GACCTGCCGTCTAGAAAAAC-3 and reverse 5-
TTGAAGTCAGAGGAGACCAC-3.  
cells/well) were plated 
onto 12 well plates and allowed to grow in 2 ml of complete medium 
for 24 h (until 70–80% confluency). Then the cells were transfected 
with amiRNA carrying vectors. The cells were harvested after 72 h and 
mRNA was extracted using TRIZOL (Invitrogen, Carlsbad, CA). 
Approximately, 5 µg of total RNA from each sample was converted into 
complementary DNA using a commercial RT-PCR kit (Invitrogen, USA).  
The optimum numbers of cycles were determined. Initial 
denaturation was performed at 94 ˚C for 1 min. The subsequent 
cycling programs consisted of denaturation at 95 ˚C for 30 sec, 
annealing temperature 59.8 ˚
 
C for 30 sec, and extension at 72 ˚C for 
30 sec, followed by a final extension at 72 ˚C for 10 min. The 
products were separated on a 1.8 % agarose gel, stained with 
Ethidium bromide, and photographed using a gel imaging system 
(Bio Rad, Hercules, CA). PCR reactions in which the first strand cDNA 
were omitted served as negative controls. To avoid technical error, 
each PCR experiment was repeated three times. 
Table 1: amiRNA and PCR templates 
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The MCF7 cells (1×103
In this study, according to the siRNA design guidelines, several 
siRNA targets were designed using ref|NM_003750.2| EIF3A, mRNA 
FASTA sequence. eIF3A siRNA targets were designed using online 
tools such as siRNA target finders such as ambion, dharmacon and 
gene script. From this 400, 85 and 10 sirna targets were obtained 
from ambion, dharmacon, gene script and microsynth and from that 
only 27, 85 and 4 siRNA targets accordingly have got 40-50% GC 
content as shown in the table 1.  cells/well) were grown in a 96-well plate for 
24 h and transfected with plasmids (pcDNA 3.1 containing amiRNA) 
using Lipofectamine 2000 (a total of 50 µl) and incubated for 24 h. 
The tetrazolium salt MTT solution (5 mg/ml; Sigma, USA) was added 
into each well and incubated at 37 ˚C for 4 h.  
The media were carefully aspirated. The blue formazan product 
converted from MTT was dissolved by the addition of 150 µl/well of 
dimethyl sulfoxide (DMSO; Sigma) and optical density (OD) readings 
were obtained using an auto reader (Biorad) at 540 nm. Each 
experiment was repeated three times.  
Statistical analyses 
Results are expressed as mean values±SD for each experimental 
group. Statistical significance of differences between groups was 
determined by the Student's t-test with Graph Pad Quick calcs 
software (online t test calculator). 
RESULTS        
Designing of amiRNA sequence 
From these six siRNA targets sequences were selected and screened 
using BLAST tool for homology detection as shown in the table 2. 
From this target sequence 1 was selected based on high GC content 




The secondary structure of specific single amiRNA is shown in the 
(fig. 1). The amiRNA construct was synthesized from SIGMA Pvt Ltd., 
and amplified by PCR using. Forward primer-5’GGATCCACTAG 
TTATTGCTCTCGAGAGTGAGC3’ and Reverse primer–5’TCTAG 
ACCCTTGAATTCCTCGGCAGTGGGCAG3’. 
Cloning of amiRNA 
The amplified amiRNA was eluted from the agarose gel using the 
QIAGEN elution protocol. The eluted product was cloned into the 
pcDNA 3.1 vector. Both the amiRNA and pcDNA 3.1 were restricted 
by using BamH1 and Xba1 restriction enzymes separately and 
ligated using DNA ligase. Ligated product was transformed into the 
(E. coli) DH5-α on the ampicillin resistant agar plate. The 
transformed colonies were amplified by PCR and the positive clones 
were confirmed by colony PCR. The PCR product was found to be 
about 123 bp length as shown in the (fig. 2). 
  
Table 2: SiRNA sequence in mRNA of eIF3A gene 
Target sequence Sense strand siRNA Antisense strand siRNA Position in gene sequence GC content 
1 CCGGAAUUGCAGCAGUAUG CAUACUGCUGCAAUUCCGG 1408 47.6% 
2 CUUUGCGUGGAUCUUCGCA UGCGAAGAUCCACGCAAAG 313 45.6% 
3 AGGAGGGGUUAUACCAGUA UACUGGUAUAACCCCUCCU 347 42.9% 
4 ACCAGCUCAUAUACUGCAA AUUGCAGUAUAUGAGCUGGU 758 38.1% 
5 AGAGCCAAACGUUUGGAAG CUUCCAAACGUUUGGCUCU 2242 42.9% 
6 GAUUACUGCGCAAGUGUGA UCACACUUGCGCAGUAAUC 4914 42.9% 
Target sequence 1: Position in gene sequence: 1408 GC content: 47.6% 
 
 




Fig. 2: Colony PCR products showing the positive clones 
indicating the presence of amiRNA construct. Lane 1: DNA 




Fig. 3: (a) RT-PCR analysis eIF3A in MCF7 cells with transfected 
plasmid vector alone and amiRNA carrying plasmids. (b) 
Relative expression of eIF3A in MCF7 cells transfected with 
plasmid vector alone and amiRNA carrying plasmids. Results 
represent the means of three separate experiments, and error 
bars represent the standard deviation of the means. (*P<0.05, 
compared with blank control group and negative control group 
respectively 
(a) 
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Accordingly, a series of experimental sets harboring control, vector 
alone and vector with amiRNA against eIF3A gene were prepared 
and their silencing efficiency was analysed using RT-PCR after 
transfection. There is perfect base pair amplification in untreated 
cell and the band intensity decreased in amiRNA treated cells (fig. 
3a). The relative ratio of eIF3A in vector alone and vector with 
amiRNA construct was found to be 0.96 and 0.64 respectively, 
compared to (non-transfected) control, (fig. 3b). These data 
illustrate that the designed amiRNA plasmid had successfully been 
transfected into the cells, and inhibited eIF3A expression. 
MTT assay 
MCF-7 cells were treated with amiRNA in time points (24 h, 48 h, 
and 72 h) and cell growth was measured by MTT assay. The 
inhibitory effect was found to be increased significantly in a time 
dependent manner (fig. 4). The results revealed that exposure of 
MCF-7 cells with amiRNA targeting eIF3A caused 50% reduction in 
cell viability at 72 h when compared to non-transfected cells. 
 
 
Fig. 4: Time dependent profile of amiRNA transfected MCF7 
cells. Results represent the means of three separate 
experiments, and error bars represent the standard deviation 
of the means. (*P<0.05, **P<0.001, compared with blank 
control group and negative control group respectively) 
 
DISCUSSION 
The eukaryotic initiation factor eIF3A is becoming an important 
target in tumor therapy because the largest subunit of the eIF3 
complex has been found to be overexpressed in several human 
cancers, including breast, cervix, oesophagus, stomach and lung [16-
19]. The increased eIF3A expression was more frequently observed 
at the early invasive stage of tumors [12].  
Thus alteration of eIF3A expression is reported in the early event of 
tumorigenesis. Indeed, knocking down eIF3A expression reversed 
the malignant phenotype of human lung cancer cell lines [4]. Over 
expression of eIF3A could support cell survival and proliferation and 
protect tumor from apoptosis [20].  
RNAi is expected to have more therapeutic benefit, compared with 
the other post-transcriptional gene silencing techniques such as 
antisense and gene knockout technology since it is easier to deliver 
and requires only small dose of miRNA to produce its silencing 
effect. Therefore in an effort to target over-expressed eIF3A in 
breast cancer cells, the RNAi effector molecule was used in our study 
which inhibited the expression of eIF3A gene. The amiR30 design 
enhances gene silencing potency [21, 22] and offers more flexibility 
in gene silencing applications, as these sequences can also be 
expressed from RNA polymerase II promoters [23]. In the present 
study, we incorporated our siRNA into miR-30 to enhance the 
silencimg efficiency. 
The inhibition of eIF3A expression in cancer cell may lead to down 
regulation of Bcl-2 antiapoptotic proteins and induce apoptosis [24]. 
The result of MTT assay showed that cell proliferation was inhibited 
remarkably in amiRNA transfected cells when compared to vector 
control.  
Chemotherapeutic resistance is also a common clinical problem for 
patients with breast cancer. Recent studies have suggested that 
overexpression of eIF3A could support cell survival and 
proliferation and protect tumor from chemotherapy induced 
apoptosis. Hence targeting of eIF3A via RNAi techology is a 
remarkable strategy to control cancer as it interferes with 
tumorogenesis; additionally, the sensitivity of breast cancer cells to 
chemotherapeutic drugs can also be taken care of using this 
technology.  
CONCLUSION 
The usage of modified endogenous miRNA in vector based 
expression system with significant silencing efficiency and 
remarkable inhibition of cell proliferation suggest that RNAi based 
gene silencing method may become one of the effective means to 
control cancer. Thus there is certainty that further focus in eFI3A 
amiRNA combination therapy with chemotherapeutic drugs will 
definitely open a new avenue in the treatment of deadly breast 
cancer.  
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